Previous Article | Next Article 
Journal of Virology, December 1999, p. 9756-9763, Vol. 73, No. 12
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
The Activation Domain of Herpesvirus Saimiri R
Protein Interacts with the TATA-Binding Protein
Kersten T.
Hall,
Alex J.
Stevenson,
Delyth J.
Goodwin,
Paul C.
Gibson,
Alex F.
Markham, and
Adrian
Whitehouse*
Molecular Medicine Unit, University of Leeds,
St. James's University Hospital, Leeds LS9 7TF, United Kingdom
Received 15 June 1999/Accepted 20 August 1999
 |
ABSTRACT |
The herpesvirus saimiri open reading frame (ORF) 50 produces two
transcripts. The first is spliced, contains a single intron, and is
detected at early times during the productive cycle, whereas the second
is expressed later and is produced from a promoter within the second
exon. Analysis of their gene products has shown that they function as
sequence specific transactivators. In this report, we demonstrate that
the carboxy terminus of ORF 50b contains an activation domain which is
essential for transactivation. This domain contains positionally
conserved hydrophobic residues found in a number of activation domains,
including the herpes simplex virus VP16 and the Epstein-Barr virus R
proteins. Mutational analysis of this domain demonstrates that these
conserved hydrophobic residues are essential for ORF 50 transactivation
capability. Furthermore, this domain is required for the interaction
between the ORF 50 proteins and the basal transcription factor
TATA-binding protein.
 |
INTRODUCTION |
Herpesvirus saimiri (HVS) is a
gammaherpesvirus of the Rhadinovirus genus that persistently
infects squirrel monkeys (Saimiri sciureus) without causing
an overt manifestation of disease. However, infection of a number of
New World primate species results in fulminant polyclonal T-cell
lymphomas and lymphoproliferative diseases (11). In
addition, HVS is capable of transforming simian and human lymphocytes
to continuous growth in vitro (4). The genome of HVS (strain
A11) consists of a unique internal low-G+C DNA segment (L-DNA) of
approximately 110 kbp, flanked by a variable number of 1,444-bp
high-G+C tandem repetitions (H-DNA) (2). Sequence analysis
indicates it shares significant homology with the herpesviruses
Epstein-Barr virus (EBV), bovine herpesvirus 4, Kaposi's
sarcoma-associated herpesvirus (or human herpesvirus 8), and murine
gammaherpesvirus 68 (1, 2, 5, 13, 14, 39, 40, 46, 51). The
genomes of these viruses are generally colinear, with large blocks of
conserved genes interspersed by relative small regions of sequence
unique to each virus (2, 5, 39, 46, 51).
Gene expression in HVS is modulated by the two major transcriptional
regulating genes encoded by open reading frame (ORF) 50 and ORF 57 (41, 42, 52, 54, 55). The ORF 57 gene product encodes a
multifunctional protein capable of both transactivation and repression
of viral gene expression. Transactivation of late viral genes occurs at
a posttranscriptional level, whereas repression of gene expression
appears to correlate with the presence of introns (54, 55).
The ORF 50 or R gene produces two transcripts. The first is spliced,
contains a single intron, and is detected at early times during the
productive cycle, whereas the second is expressed later and is produced
from a promoter within the second exon. The spliced transcript is
fivefold more potent in activating the delayed-early ORF 6 promoter.
However, the function of the nonspliced transcript is unclear (41,
52). Further analysis of the ORF 50 gene products have
demonstrated that they activate transcription directly following
interactions with promoters containing a specific sequence motif.
Deletion and gel retardation analysis have identified the consensus ORF
50 recognition sequence, CCN9GG, required for ORF 50 binding (53). These response elements have significant
homology to the EBV R response element consensus sequence, GNCCN9GGNG. It has been shown by guanine methylation
studies that the CCN9GG motif is essential for EBV R
binding and suggests that R binds to adjacent major grooves of the DNA
(16-18).
In addition to the DNA motif, to which sequence specific
transactivators bind, at least two functional components are essential. These are inherent to the protein itself and include structural domains
which (i) direct the protein to its target, the DNA-binding domain, and
(ii) facilitate the initiation of RNA transcription, the activation
domain, by recruiting cellular proteins at the promoter (38,
43). The latter is facilitated by the interaction of the viral
activation domain(s) with basal transcription factors of the host,
which has been demonstrated for several viral transactivators, including adenovirus E1A (26, 36), herpes simplex virus VP16 (23, 48), the EBV Z (28) and R (34)
proteins, human T-cell leukemia virus (HTLV-1) Tax1 protein
(6), and human immunodeficiency virus type 1 (HIV-1) Tat
(25).
Analysis of the ORF 50 homologue, the EBV R protein, demonstrated that
the deletion of amino acid sequences near the carboxy terminus ablated
its transactivation activity without affecting its ability to bind DNA
(21, 33). This finding suggested that the domain(s) of EBV
R, which contact cellular transcription factors to facilitate viral
transcription, are contained in the carboxy terminus of the protein. To
specifically identify the activation domain(s), different segments of
the EBV R were linked to the DNA-binding domain of the yeast
transactivator GAL4 (20). These GAL4-R fusion proteins were
then assayed for the ability to activate the adenovirus E1B promoter
with an upstream GAL4 DNA-binding site, linked to the chloramphenicol
acetyltransferase (CAT) reporter gene. The carboxy terminus of the EBV
R gene was demonstrated to be a potent activator of transcription.
Characterization of the activation domain of EBV R revealed three
overlapping copies of a motif containing positionally conserved
hydrophobic amino acids present in a number of other transactivators,
including ORF 50, GAL4 (24), HSV-1 VP16 (10), and
adenovirus E1A (26). Furthermore, Hardwicke et al.
(20) showed that the carboxy terminus of the HVS ORF 50 protein was capable of activating transcription in the assay described.
However, it was not determined whether these sequences were essential
to activate transcription. In this report, we demonstrate that the
carboxy terminus is essential for ORF 50 transactivation and for the
interaction between the ORF 50 proteins and the general cellular
transcription factor TATA-binding protein (TBP).
 |
MATERIALS AND METHODS |
Plasmid constructs.
The 3' deletion series which contained
the putative ORF 50b transcription start site and 71,188 bp of the
published sequence (2) but removed larger portions of the
carboxy terminus was constructed by PCR amplification from viral DNA
(strain A11) by using the forward primer 5'-CAG AAT TCG ATG CAG CGC CTT
GTA TAT ACT and a series of reverse primers consisting of
1 (5'-CAG
AAT TCC TAG CCA AGG TCT TCA ATA TCT AC),
2 (5'-CAG AAT TCC TAT GAA CAT AAA ACT GGA GGT GC),
3 (5'-CAG AAT TCC TAG TCA TCT GTT TCT GCT
TCG T),
4 (5'-CAG AAT TCC TAC ACA GAT GAT GAA GTA CAT GG), and
5
(5'-CAG AAT TCC TAT GGT ACT GTA GGT AAC ATT TCA G); these oligonucleotides incorporated EcoRI restriction sites for
the convenient cloning of the PCR products. Each fragment was inserted into the eukaryotic expression vector pBKCMV (Stratagene) to derive pBK50
1-5.
A range of mutants containing site-directed changes within the
hydrophobic residues of the carboxy terminus of ORF 50b were generated
by a PCR-based method which incorporated the alteration of one or more
of the conserved residues to glycine (underlined) in the 3' primer: M1
(5'-CGC GAA TTC TTC ATC ATT TAA AAA ATC TTG TAA AGA CAT AGG AAA TGA
GCC GCC), M2 (5'-CGC GAA TTC TTC ATC ATT TAA AAA ATC TTG
GCC AGA CAT AGG AAA TGA TAA GCC), M3 (5'-CGC GAA TTC TTC
ATC ATT TAA GCC ATC TTG TAA AGA CAT AGG AAA TGA TAA GCC), M4 (5'-CGC GAA TTC TTC ATC ATT GCC AAA ATC TTG TAA AGA CAT
AGG AAA TGA TAA GCC), M5 (5'-CGC GAA TTC TTC ATC ATT GCC
AAA ATC TTG GCC AGA CAT AGG AAA TGA TAA GCC), M6 (5'-CGC GAA TCC TTC
ATC ATT GCC GCC ATC TTG TAA AGA CAT AGG AAA TGA TAA GCC), M7 (5'-CGC
GAA TTC TTC ATC ATT GCC GCC ATC TTG GCC AGA CAT
AGG AAA TGA TAA GCC), and M8 (5'-CGC GAA TTC TTC ATC ATT GCC GCC ATC
TTG GCC AGA CAT AGG AAA TGA GCC GCC). In
addition, a site-directed mutant containing alterations in residues
flanking the conserved hydrophobic residue domain (M9 [5'-CGC GAA TTC
TTC ATC ATT TAA AAA ATC TTG TAA AGA CAT AGG AAA TGA TAA GCC AAG GTC TTC
AAT TAC TAC GCC GCC]) was used as a control. These
oligonucleotides incorporated EcoRI restriction sites for
the convenient cloning of the PCR products. Each fragment was inserted
into the transfer vector pBKCMV to derive pBK50M1-9.
In producing the construct pGST50, a 332-bp fragment containing bp
71845 to 72177 of the published sequence was generated
by PCR using the
primers 5'-CCG GAA TCC GCC AGC CCT AGA AAG CTT
and 5'-CCG GAA TTC GGT
TGA ATG TTC GAT GAG; these oligonucleotides
incorporated
EcoRI restriction sites to facilitate subcloning
into the
expression vector pGEX-2T, yielding pGST50. In addition,
pGST50C
contains the last 50 amino acids of the ORF 50 carboxy
terminus fused
with glutathione
S-transferase (GST). The carboxy-terminal
ORF 50 fragment was generated by PCR amplification from viral
DNA
(strain A11), using the forward primer 5'-CGC GGA TCC ACA
GAT GAC AAT
ATA TTA GCT and reverse primer 5'-CCG GAA TTC TAG
TTA GAC ATT ACA C;
these oligonucleotides incorporated
BamHI and
EcoRI restriction sites, respectively, to facilitate
subcloning
into the expression vector pGEX-2T to derive
pGST50C.
In vitro transcription-translation.
Protein expression from
individual clones of the pBK50 deletion series was analyzed by in vitro
transcription-translation using the TNT system (Promega) according to
the manufacturer's instructions. Transcription was initiated from the
bacteriophage T3 promoter situated upstream of the cloned ORF 50b
fragments in pBKCMV. The synthesized products were then separated on a
12% polyacrylamide gel and detected by autoradiography.
Polyclonal antibody generation.
Polyclonal antisera was
raised against a portion of recombinant ORF 50 protein. The ORF 50 fragment was expressed as a GST fusion protein in Escherichia
coli DH5
and purified from crude lysates by affinity
chromatography with glutathione-Sepharose 4B as specified by the
manufacturer (Pharmacia Biotech). The purified recombinant protein was
used to generate a polyclonal antibody in New Zealand White rabbits by
using standard protocols.
Viruses, cell culture, and transfections.
HVS (strain A11)
was propagated in owl monkey kidney (OMK) cells which were maintained
in Dulbecco modified Eagle medium (Life Technologies) supplemented with
10% fetal calf serum (FCS). Plasmids used in the transfections were
prepared by using Qiagen plasmid kits according to the manufacturer's
directions. OMK cells were seeded at 5 × 105 cells
per 35-mm-diameter petri dish 24 h prior to transfection. Transfections were performed with DOTAP (Boehringer Mannheim) as
described by the manufacturer, using 2 µg of the appropriate DNAs.
Immunofluorescence analysis.
Cells were fixed with 4%
formaldehyde in phosphate-buffered saline (PBS), washed in PBS, and
permeabilized in 0.5% Triton X-100 for 5 min. The cells were rinsed in
PBS and blocked by preincubation with 1% (wt/vol) nonfat milk powder
for 1 h at 37°C. A 1:20 dilution of anti-ORF 50 antibody was
layered over the cells and incubated for 1 h at 37°C.
Fluorescence-conjugated anti-rabbit immunoglobulin (1:50 dilution;
Dako) was added for 1 h at 37°C. After each incubation step,
cells were washed extensively with PBS. The immune fluorescence slides
were observed in a Zeiss Axiovert 135TV inverted microscope with a
Neofluar 40× oil immersion lens.
CAT assay.
Cell extracts were prepared 48 h after
transfection and incubated with [14C]chloramphenicol in
the presence of acetyl coenzyme A as described previously
(15). The percentage acetylation of chloramphenicol was
quantified by scintillation counting (Packard) of appropriate regions
of the thin-layer chromatography plate.
Immunoprecipitation analysis.
OMK cells were seeded at
106 cells per 35-mm-diameter petri dish and washed in
labelling medium (minimum essential medium minus methionine and
cysteine plus 2% FCS). Controls remained untransfected, were
transfected with 2 µg of the appropriate DNAs, or were infected with
HVS at a multiplicity of infection (MOI) of 1. The cells were incubated
with 2 ml of the labelling medium containing 200 µCi of Pro-mix
35S in vitro cell labelling mix plus 10% FCS (Amersham)
for 24 h. Cells were harvested and lysed with lysis buffer (0.3 M
NaCl, 1% Triton X-100, 50 mM HEPES buffer [pH 8.0]) containing
protease inhibitors (leupeptin and phenylmethylsulfonyl fluoride
[PMSF]). For each immunoprecipitation, 20 µl of the anti-ORF 50 polyclonal antibody was incubated with protein A-Sepharose beads
(Pharmacia Biotech) for 16 h at 4°C. The beads were then
pelleted and washed four times in PBS. Each cell lysate was then added
to the beads and incubated for 16 h at 4°C. The beads were then
pelleted, washed four times in lysis buffer, and resuspended in Laemmli
buffer; precipitated polypeptides were resolved on a sodium dodecyl
sulfate (SDS)-12% polyacrylamide gel and analyzed by autoradiography.
Gel retardation assay.
Gel retardation assays were performed
as previously described (53). Briefly, two oligonucleotides
encoding the ORF 50 response elements, 5'-TTA AAA ATT TCC TGT CAA TGT
GGT TTG CTT GG and 5'-CCA AGC AAA CCA CAT TGA CAG GAA ATT TTT AA, were
annealed and labelled by using T4 polynucleotide kinase in the presence
of [
-32P]dATP. The radiolabelled oligonucleotides were
incubated for 20 min with nuclear extracts of untransfected OMK cells
or cells transfected with the appropriate DNAs prepared by the method
of Andrews and Faller (3). The binding reactions were
performed in 20 µl of binding buffer (100 mM KCl, 20 mM HEPES [pH
7.3], 1% glycerol, 0.2 mM EDTA, 5 mM MgCl2, 4 mM
dithiothreitol, 0.5 mM PMSF) with 1 µg of poly(dI-dC) as an
unspecific competitor. The protein-nucleic acid complexes were
separated on a 5% polyacrylamide gel, run in 1% Tris-borate-EDTA
(TBE) buffer, and detected by autoradiography.
Immunoblot analysis.
Immunoblot analysis was performed with
the immunoprecipitation samples described above. Precipitated
polypeptides were resolved on an SDS-12% polyacrylamide gel and then
soaked for 10 min in transfer buffer (25 mM Tris, 192 mM glycine, 20%
[vol/vol] methanol, 0.1% SDS). The proteins were transferred to
nitrocellulose membranes by electroblotting for 3 h at 250 mA.
After transfer, the membranes were soaked in PBS and blocked by
preincubation with 2% (wt/vol) nonfat milk powder for 2 h at
37°C. Membranes were incubated with a 1/1,000 dilution of the
anti-TFIID monoclonal antibody (Promega), washed with PBS, and
incubated for 1 h at 37°C with a 1/1,000 dilution of anti-mouse
immunoglobulin conjugated with horseradish peroxidase (Dako) in
blocking buffer. After five washes with PBS, the nitrocellulose
membranes were developed by using enhanced chemiluminescence (Pierce)
according to the manufacturer's directions.
GST pulldown assay.
The ORF 50 carboxy terminus was
expressed as a GST fusion protein in E. coli DH5
. A fresh
overnight culture of transformed E. coli was diluted 1 in 20 with Luria-Bertani medium containing ampicillin (100 µg/ml). After
growth at 37°C for 2 h, the culture was induced with 1 mM
isopropyl-
-D-thiogalactopyranoside and grown at 37°C
for a further 4 h. The cells were harvested by centrifugation and
resuspended in 0.1× lysis buffer (100 mM Tris-HCl [pH 8.0], 200 mM
NaCl, 1% Triton X-100, 1 mM EDTA, 0.5 mM PMSF). Cells were sonicated
and stored on ice for 30 min, and cellular debris was pelleted. The
recombinant protein was purified from crude lysates by incubation with
glutathione-Sepharose 4B affinity beads as specified by the
manufacturer (Pharmacia Biotech). The beads containing the GST-ORF 50 carboxy-terminus fusion were then incubated with OMK cell lysates
previously lysed with lysis buffer (0.3 M NaCl, 1% Triton X-100, 50 mM
HEPES buffer [pH 8.0]) containing protease inhibitors (leupeptin and
PMSF) for 16 h at 4°C. The beads were then pelleted, washed four
times in lysis buffer, and resuspended in Laemmli buffer; precipitated
polypeptides were resolved on an SDS-12% polyacrylamide gel. The
proteins were then transferred to nitrocellulose membranes by
electroblotting and probed for TFIID as described above.
 |
RESULTS |
Deletion analysis of the carboxy terminus of ORF 50.
To
analyze the sequences which are essential for transactivation by the
ORF 50 protein, a 3' deletion series of the ORF 50b coding region was
produced. The carboxy-terminal deletion series contained the putative
ORF 50b transcription start site at 71,188 bp of the published sequence
(2) but removed larger portions of the carboxy terminus.
Each fragment was inserted into the transfer vector pBKCMV (Stratagene)
to derive pBK50
1-5 (Fig. 1). All
constructs were confirmed by DNA sequencing (data not shown). In
addition, the complete coding region of ORF 50b contained as a
HincII cassette was excised from pAWHincII
(9) and inserted into pBKCMV to derive the control plasmid
pBK50b.

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 1.
Schematic representation of the carboxy-terminus
deletion series of the ORF 50b protein. A series of 3' mutants were
constructed by PCR amplification and ligated into the eukaryotic
expression vector pBKCMV to derive pBK50 1-5.
|
|
To investigate protein expression from each clone of the pBK50 deletion
series, in vitro transcription-translation was performed
with the TNT
system (Promega). Transcription was initiated from
the bacteriophage T3
promoter situated upstream of the cloned
ORF 50b fragments in pBKCMV.
Results showed that pBK50b generated
a product of approximately 41 kDa
and that each ORF 50b deletion
construct supported the production of a
major protein species.
Moreover, the apparent molecular weights of
these proteins were
consistent with consecutive deletions of the ORF
50b gene product,
ranging from approximately 38.5 kDa following
expression from
pBK50

1 to 29 kDa for pBK50

5 (Fig.
2), although the proteins
from pBK50b and
pBK50

1 were produced at low levels.

View larger version (116K):
[in this window]
[in a new window]
|
FIG. 2.
In vitro transcription-translation analysis of ORF 50 deletion series. Protein expression from pBK50b (lane 1), pBK50 1
(lane 2), pBK50 2 (lane 3), pBK50 3 (lane 4), pBK50 4 (lane 5),
and pBK50 5 (lane 6) was analyzed by in vitro
transcription-translation. Transcription was initiated from the
bacteriophage T3 promoter situated upstream of the cloned ORF50b
fragments in pBKCMV. The synthesized products (indicated by arrows)
were then separated on a 12% polyacrylamide gel and detected by
autoradiography. Sizes are indicated in kilodaltons.
|
|
Furthermore, to determine the expression levels and subcellular
localization of ORF 50b and the deletion series, a polyclonal
antiserum
was raised against a portion of recombinant ORF 50 protein.
Unfortunately, the ORF 50 polyclonal antiserum did not react on
a
Western blot of HVS-infected or ORF 50-transfected cells (data
not
shown). Therefore, to determine if each deletion produced
a protein
product, immunofluorescence analysis of HVS-infected
and transient
transfected cells was performed. Immunofluorescence
analysis of
HVS-infected cells resulted in a strong fluorescence
of the nuclei of
infected cells. Similar results were observed
with pBK50b- and
pBK50

1-transfected cells; no reaction was observed
with
untransfected cells (Fig.
3). Similar
nuclear immunofluorescence
staining was observed with
pBK50

2-5-transfected cells (data not
shown). This finding suggested
that each deletion construct produced
a protein which localized to the
cell nucleus.

View larger version (93K):
[in this window]
[in a new window]
|
FIG. 3.
Expression levels and subcellular localization of ORF
50b and 50 1 proteins. A polyclonal antiserum was raised against a
portion of recombinant ORF 50 protein and used in immunofluorescence
analysis of cells mock transfected (i), HVS infected (MOI of 1) (ii),
and transiently transfected with pBK50b (iii) and pBK50 1 (iv).
|
|
The carboxy terminus is essential for ORF 50 transactivation of the
ORF 6 promoter.
To identify the sequences essential for ORF 50 transactivation activity, 1 µg of each deletion plasmid was
cotransfected with 1 µg of pAWCAT2. This plasmid contains the CAT
coding region under the control of the ORF 50-responsive ORF 6 promoter
(52). Plasmid pBK50b was also used in the assay as a
positive control. Cells were harvested after 48 h and assayed for
CAT activity by standard methods (15) (Fig.
4). Reduced CAT activity was observed
when the deletion constructs were used to transactivate pAWCAT2.
However, pBK50b was shown to transactivate the ORF 6 promoter to levels similar to those found previously (52). This suggested that the sequences contained within bp 72350 to 72402 of the published sequence, which were deleted in pBK50
1, are essential for
transactivation by the ORF 50b gene product.

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 4.
Analysis of the ORF 50b carboxy-terminus deletion
series. OMK cell monolayers were transfected with 1 µg of pAWCAT2 or
cotransfected 1 µg of each deletion plasmid, using DOTAP transfection
reagent (Boehringer Mannheim) according to the manufacturer's
instructions. Cells were harvested at 48 h posttransfection, and
cell extracts were assayed for CAT activity. Percentages of acetylation
were calculated by the scintillation counting of the appropriate
regions of the chromatography plate and are shown in graphical format;
the variations between three replicated assays are indicated.
|
|
The carboxy-terminal 50
1 mutant produces a stable protein which
binds to the ORF 50 response elements.
To determine whether the
lack of transactivation of the ORF 6 promoter was due to the removal of
the ORF 50b carboxy terminus, or whether the removal of these sequences
affected the protein stability or DNA-binding ability of the ORF 50b
protein, immunoprecipitation and gel retardation assays were performed
with pBK50
1. First, to determine whether the expression vector
pBK50
1 produced a stable protein compared to the wild-type 50b
protein in transfected and infected cells, immunoprecipitation analysis
was performed. OMK cells remained untransfected, were transfected with
2 µg of pBK50b or pBK50
1, or were infected with HVS at an MOI of
1. The cells were then incubated in the presence of 35S in
vitro cell labelling mix for 24 h and harvested, and cell lysates
were utilized in immunoprecipitation analysis using the anti-ORF 50 polyclonal antibody. The results demonstrate that a protein of the
correct size is produced and precipitated with the anti-ORF 50 antibody
from cell lysates transfected with pBK50
1 (Fig.
5a). In addition, the precipitated
protein was produced in quantities similar to those for the wild-type
protein, suggesting that deletion of the last 14 amino acids does not
affect ORF 50 protein stability.

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 5.
The carboxy-terminal ORF 50 1 construct produces a
stable protein which binds to the ORF 50 response elements. (a) OMK
cells were seeded at 106 cells per 35-mm-diameter petri
dish and washed in labelling medium. Controls remained untransfected
(lane 1) or were transfected with 2 µg of pBK50 1 (lane 2), pBK50
(lane 3) or infected with HVS (lane 4). The cells were incubated in
labelling medium, harvested, and then lysed after 24 h. For each
immunoprecipitation, 20 µl of the anti-ORF 50 polyclonal antibody was
incubated with protein A-Sepharose beads for 16 h at 4°C.
Immunoprecipitations were then performed with each cell lysate, using
the anti-ORF 50 antibody. Beads were then pelleted, washed, and
resuspended in Laemmli buffer; precipitated polypeptides were resolved
on an SDS-12% polyacrylamide gel and analyzed by autoradiography. (b)
Gel retardation assays were performed as previously described
(53). Briefly, the ORF 50 response elements contained in a
set of oligonucleotides were annealed and radiolabelled. These were
incubated with nuclear extracts of untransfected OMK cells (lane 1) or
cells transfected pBK50b (lane 2) and pBK50 1 (lane 3). The
protein-nucleic acid complexes (indicated by arrow) were separated on a
5% polyacrylamide gel, run in 1% TBE buffer, and detected by
autoradiography.
|
|
We have previously determined, using deletion analysis and gel
retardation assays, the ORF 50 response elements contained
within the
ORF 6 promoter to which ORF 50b binds (
54). To determine
if
the 50

1 protein could bind to these sequences, gel retardation
assays were performed. Radiolabelled probes encoding the ORF 50
response elements were incubated with DNA-binding protein extracts
from
untransfected cells and cells transfected with pBK50b or
pBK50

1. The
protein-nucleic acid complexes were then separated
on a polyacrylamide
gel (Fig.
5b). Results show the formation
of a retarded complex using
the extracts of cells transfected
with pBK50b and pBK50

1. Unlabelled
oligonucleotide was shown
to compete with this reaction (data not
shown), further indicating
that the protein produced from pBK50

1 has
the ability to specifically
bind to the ORF 50 response elements. It
must be noted that the
50

1 protein seems to bind the
oligonucleotides at a greater affinity;
this observation is currently
under investigation. However, these
two experiments demonstrate that
pBK50

1 produced a stable protein
which could bind to the ORF 50 response elements. This result
further suggests that the sequences
contained within the carboxy-terminal
14 amino acids are essential for
transactivation by the ORF 50b
gene
product.
Mutational analysis of the ORF 50b transactivation domain.
The
deletion of the carboxy-terminal 14 amino acids abrogates the
transactivating capability of ORF 50b. As previously described, the
carboxy terminus of ORF 50 contains a motif of positionally conserved
hydrophobic amino acids homologous with the EBV R protein. To determine
the importance of the conserved hydrophobic amino acids for ORF 50b
transactivation activity, we constructed a range of site-directed
mutations (Fig. 6a) by a PCR-based method
which incorporated the alteration of one or more of the conserved
residues to glycine. In addition, residues flanking the hydrophobic
residue domain were altered to glycine to serve as an appropriate
control. Each fragment was inserted into the transfer vector pBKCMV to derive pBK50M1 to pBK50M9. All constructs were confirmed by DNA sequencing (data not shown). To identify the residues within the ORF
50b transactivation domain which are essential for ORF 50 transactivation, 1 µg of each construct was cotransfected with 1 µg
of pAWCAT2. Cells were harvested after 48 h and assayed for CAT
activity (Fig. 6b). Results show that the mutations of asparagine residues at bp 72334 to 72337 of the published sequence, which flank
the conserved hydrophobic residues, had little, if any, effect on ORF
50 transactivation capability. However, mutation of the conserved
leucine residue at bp 72361 of the published sequence reduced CAT
activity by approximately 10%. Moreover, single mutations at the
conserved leucines at bp 72379 and 72391 and phenylalanine at bp 72388 of the published sequence proved highly detrimental to ORF 50b
transactivation, reducing CAT activity by 57, 75, and 72%,
respectively. Furthermore, multiple substitutions of these residues
completely abrogated biological activity, showing that these conserved
hydrophobic residues are essential for ORF 50 transactivation activity.

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 6.
Mutational analysis of the ORF 50b transactivation
domain. (a) The carboxy-terminal 14 amino acids contain a motif of
positionally conserved hydrophobic amino acids homologous with the EBV
R protein (boldface). A range of site directed mutations were
constructed such that one or multiple conserved hydrophobic residues
were replaced with a glycine residue (boldface). (b) OMK cell
monolayers were transfected with 1 µg of pAWCAT2 or cotransfected
with 1 µg of each 50b mutation plasmid, using DOTAP transfection
reagent. Cells were harvested at 48 h posttransfection, and cell
extracts were assayed for CAT activity. Percentages of acetylation were
calculated by scintillation counting of the appropriate regions of the
chromatography plate and are shown in graphical format; the variations
between three replicated assays are indicated.
|
|
The carboxy-terminal mutation 50M7 produces a stable protein which
binds to the ORF 50 response elements.
To determine whether these
mutations within the hydrophobic residues, specifically M7, affect
protein stability or the ability of ORF 50 to bind to the response
elements' immunofluorescence, immunoprecipitations and gel retardation
assays were performed as described above. To determine if pBK50M7
produced a protein product which localized to the nucleus,
immunofluorescence analysis of pBK50M7-transfected cells was performed.
A strong nuclear fluorescence was observed in cells transfected with
pBK50M7, as previously described (Fig.
7a). Similar results were observed with
the remaining mutant constructs in transfected cells (data not shown).
To determine whether the expression vector pBK50M7, which abrogated
transactivation capability of the ORF 50b protein, produced a stable
protein compared to wild-type 50b, immunoprecipitations were performed.
Results demonstrate that a stable protein product is produced, at
levels similar to those for the wild-type protein, from pBK50M7 (Fig. 7b). Furthermore, to determine if the 50M7 protein could bind to these
sequences, gel retardation assays were performed. Results show the
formation of a retarded complex, using extracts of cells transfected
with pBK50b and pBK50M7 (Fig. 7c). Unlabeled oligonucleotide was shown
to compete with this reaction (data not shown), further indicating that
the protein produced from pBK50M7 has the ability to specifically bind
to the ORF 50 response elements. These three experiments demonstrate
that the mutations within the hydrophobic residues, specifically the
mutations contained within 50M7, of the ORF 50 transactivation domain
are responsible for the lack of transactivation by the ORF 50b gene
product.

View larger version (53K):
[in this window]
[in a new window]
|
FIG. 7.
The ORF 50 carboxy-terminal mutation, 50M7, produces a
stable protein which binds to the ORF 50 response elements. (a)
Subcellular localization of ORF 50M7 protein, determined by
immunofluorescence analysis of cells mock transfected (i) or
transfected with pBK50M7 (ii). (b) OMK cells were seeded at
106 cells per 35-mm-diameter petri dish and washed in
labelling medium. Controls remained untransfected (lane 1) or
transfected with 2 µg of pBK50b (lane 2) or pBK50M7 (lane 3). The
cells were incubated in labelling medium, harvested, and then lysed
after 24 h. For each immunoprecipitation, 20 µl of the anti-ORF
50 polyclonal antibody was incubated with protein A-Sepharose beads for
16 h at 4°C. Immunoprecipitations were then performed with each
cell lysate, using the anti-ORF 50 antibody. These samples were then
pelleted, resuspended in Laemmli buffer, resolved on an SDS-12%
polyacrylamide gel, and analyzed by autoradiography. (c) Gel
retardation assays were performed as previously described
(53). Briefly, the ORF 50 response elements contained in a
set of oligonucleotides were annealed, radiolabelled and then incubated
with nuclear extracts of untransfected OMK cells (lane 1) or cells
transfected pBK50b (lane 2) and pBK50M7 (lane 3). The protein-nucleic
acid complexes (indicated by the arrow) were separated on a 5%
polyacrylamide gel, run in 1% TBE buffer, and detected by
autoradiography.
|
|
The hydrophobic residues contained within the ORF 50 transactivation domain, specifically 50M7, are essential for the
interaction with TBP.
Hydrophobic residues have been proposed to
be important in protein-protein interactions between activating
proteins and the cellular transcription machinery. To determine if the
conserved hydrophobic residues within the carboxy-terminal activation
domain were essential for interactions with cellular transcription
factors, immunoblot analysis was performed with pBK50M7-transfected
cells. Radiolabelled cell lysates from either untransfected cells or cells transfected with pBK50b or pBK50M7 were incubated with protein A-Sepharose beads, previously bound to the anti-ORF 50 polyclonal antibody. Immunofluorescence on duplicate samples was performed to
ensure transfection efficiency (data not shown). Polypeptides precipitated from transfected cellular extracts by the anti-ORF 50 antibody were then resolved by SDS-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane, and immunoblot detection was performed with an anti-TFIID monoclonal antibody which specifically recognizes TBP. Immunoprecipitations using the pBK50b-transfected cell
lysate specifically recognized the TBP. However, the pBK50M7 (containing mutations within the acidic transactivation domain) cell
lysate did not react with the antibody (Fig.
8). This finding suggests that the
hydrophobic residues contained within the carboxy-terminal acidic
transactivation domain, specifically the mutations containing within
M7, are essential for the interaction of ORF 50b with the cellular
transcription factor TBP.

View larger version (54K):
[in this window]
[in a new window]
|
FIG. 8.
The hydrophobic residues contained within the
transactivation domain are required for the interaction with TBP.
Immunoblot analysis was performed with the immunoprecipitation samples,
untransfected control cells (lane 1) and cells transfected with 2 µg
of pBK50b (lane 2) or pBK50M7 (lane 3). Polypeptides were resolved on
an SDS-12% polyacrylamide gel and then transferred to nitrocellulose
membranes. After transfer, the membranes were blocked, incubated with a
1/1,000 dilution of the anti-TFIID monoclonal antibody, washed, and
incubated for 1 h at 37°C with a 1/1,000 dilution of anti-mouse
immunoglobulin conjugated with horseradish peroxidase in blocking
buffer. After five washes with PBS, the nitrocellulose membranes were
developed, using enhanced chemiluminescence.
|
|
The carboxy-terminal domain of ORF 50 is sufficient for the
interaction with TBP.
To determine whether the carboxy-terminal
domain is sufficient for the interaction between the ORF 50b protein
and TBP, GST pulldown analysis was performed. The ORF 50 carboxy
terminus was expressed as a GST fusion protein, or the control GST
alone, in E. coli and purified from crude lysates by
incubation with glutathione-Sepharose 4B affinity beads (Fig.
9a). These protein bound beads were then incubated with an OMK cell lysate. The beads were then pelleted and
washed, and the cellular proteins precipitated by GST or the GST-ORF 50 fusion protein were resolved on an SDS-12% polyacrylamide gel. The
proteins were then transferred to nitrocellulose membranes by
electroblotting and probed for TBP as previously described. Results
demonstrate that GST alone did not precipitate TBP but TBP did interact
with the GST-ORF 50 carboxy terminus fusion protein (Fig. 9b). This
finding suggests that the ORF 50 carboxy terminus is responsible for
the interaction with the cellular transcription factor TBP.

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 9.
The ORF 50 transactivation domain is sufficient for the
interaction with TBP. (a) The control GST alone (lane 1) and the
GST-ORF 50 carboxy terminus fusion protein (lane 2) were expressed in
E. coli DH5 and purified from crude lysates by incubation
with glutathione-Sepharose 4B affinity beads. (b) The beads containing
GST alone (lane 1) or the GST-ORF 50 carboxy terminus fusion protein
(lane 2) were then incubated with OMK cell lysates. The beads were then
pelleted, washed, resuspended in Laemmli buffer, and resolved on an
SDS-12% polyacrylamide gel. The proteins were then transferred to
nitrocellulose membranes by electroblotting and probed for TFIID.
|
|
 |
DISCUSSION |
Transcriptional activators have the ability to stimulate in vitro
the assembly of transcription preinitiation complexes (9, 31) as well as transcriptional elongation by RNA polymerase II
(57). This activation directly or indirectly is dependent on
the interaction between the general transcriptional machinery and the
transcriptional activators. Transcriptional activators have at least
two distinct domains, the DNA-binding domain and the activation domain
(43). The activation domain enhances the transcription of
target genes. Three major classes of activation domains have been
identified according to their amino acid composition: acidic negatively
charged, proline rich, and glutamine rich (38).
In this report, we demonstrate that the HVS ORF 50 protein contains an
acidic transactivation domain within the carboxy terminus, which is
essential for the transactivating capability of the protein. Analysis
of the HVS ORF 50 activation domain indicates that it contains
positionally conserved hydrophobic residues with activation domains
found in a variety of viral, yeast, and mammalian transcriptional activators, including HSV-1 VP16, EBV R, GAL4, GCN4, Sp1, and CTF
(10, 20). Site-directed mutagenesis indicates that these conserved hydrophobic residues are required for full transactivation activity of the ORF 50b protein, further suggesting that these hydrophobic residues are essential components of the ORF 50 activation domain. Moreover, extensive mutational analysis of the activation domains present in a number of other proteins, such as VP16
(10), p53 (30), Sp1 (12), c-Fos
(37), E1a (29), and GAL4 (27), have
shown that these conserved bulky hydrophobic residues are also
essential for transcriptional activation. Hydrophobic residues may be
involved in the direct protein-protein interactions between the
activation domain and the cellular transcription machinery and/or in
maintaining the structure of the activation domain. Circular dichroism
spectroscopy has demonstrated, however, that the spectra of the
wild-type p53 activation domain and a mutated activation domain had no
significant difference in structure (7). This finding
suggests that the hydrophobic residues play a role in the interaction
of the activation domain and cellular transcription factors.
It is interesting that the activation domain of the ORF 50 homologue,
EBV R protein, is comprised of two domains, a potent acidic activation
domain and a proline-rich domain. It has been shown that the acidic
region, which contains three overlapping copies of a motif containing
the conserved hydrophobic residues, plays a central role in
transcriptional activation (20). However, although the
proline-rich domain has alone no activity, it increases the R
protein-activating potential in a cell-specific manner (34). This finding suggests that this proline-rich domain may be required for
stabilizing the interaction of the EBV R transactivation domain and
target molecules. However, although analysis of the HVS ORF 50 carboxy
terminus shows that a number of proline residues are present, we
believe that this region does not constitute a proline-rich domain.
Mutational analysis of these proline residues will help in addressing
their role, if any, in ORF 50's transactivation capability.
In addition, we have preliminary data to suggest that the ORF 50 transactivation domain is required for the interaction of ORF 50 with
TBP. A key role in transcription initiation by RNA polymerase II is the
binding of a multisubunit complex, TFIID, to the TATA element close to
the transcription start site. The major component of the TFIID complex
is TBP, which is also required for transcription of RNA polymerase I
and III promoters. In addition, a number of TBP-associated factors are
assembled into the TFIID (reviewed in references 45
and 50) and interact with more distant transcription
factors, binding to enhancer elements and to RNA polymerase II and its
accessory proteins, allowing transcription initiation. Many activation
domains have been shown to interact with TBP. These include the acidic
activation domains of VP16 (23, 48), p53 (8, 32, 35,
47, 49), c-Fos and c-Jun (44), c-Myc (22),
v-Rel and c-Rel (56), E2F-1 (19), the EBV Z
(28) and R (34) proteins, HTLV-1 Tax1 protein
(6), and HIV-1 Tat (25). The direct interaction
between the ORF 50 transactivation domain and a component of the
cellular transcription machinery may have several functions. It may be
involved in the stabilization of the interaction of TFIID with promoter
DNA, as shown for EBV Zta (28). Second, recruitment of TFIIB
into the initiation complex may be enhanced in the presence of ORF 50, as demonstrated in assays using the VP16 transactivation domain, or in
the recruitment of other general transcription factors into the
initiation complex. Alternatively, it may play a role in enhancing the
rate of transcription elongation. The data reported herein suggests a
preliminary finding of the interaction between ORF 50 and TBP. The
specific role of the ORF 50-TBP interaction requires further investigation.
In summary, we have demonstrated that the carboxy terminus of ORF 50 is
essential for transactivation. It contains a motif of positionally
conserved hydrophobic amino acids found in a number of activation
domains. Mutational analysis has shown that these conserved hydrophobic
domains are essential for transcriptional activation and for the
interaction between the ORF 50 proteins and the cellular transcription
factor TBP.
 |
ACKNOWLEDGMENTS |
This work was supported in part from grants from the Medical
Research Council (MRC), Yorkshire Cancer Research, and the West Riding
Medical Research Trust. A.W. is a recipient of an MRC fellowship.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Molecular
Medicine Unit, University of Leeds, St. James's University Hospital,
Leeds LS9 7TF, United Kingdom. Phone: 44 (0)113 2066328. Fax: 44 (0)113 2444475. E-mail: a.whitehouse{at}leeds.ac.uk.
 |
REFERENCES |
| 1.
|
Albrecht, J. C., and B. Fleckenstein.
1990.
Structural organization of the conserved gene block of herpesvirus saimiri coding for DNA polymerase, glycoprotein B, and major DNA binding protein.
Virology
174:533-542[Medline].
|
| 2.
|
Albrecht, J. C.,
J. Nicholas,
D. Biller,
K. R. Cameron,
B. Biesinger,
C. Newman,
S. Wittman,
M. A. Craxton,
H. Coleman,
B. Fleckenstein, and R. W. Honess.
1992.
Primary structure of the herpesvirus saimiri genome.
J. Virol.
66:5047-5058[Abstract/Free Full Text].
|
| 3.
|
Andrews, N. C., and D. V. Faller.
1991.
A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells.
Nucleic Acids Res.
19:2499[Free Full Text].
|
| 4.
|
Beisinger, B.,
I. Muller-Fleckenstein,
B. Simmer,
G. Lang,
S. Wittmann,
E. Platzer,
R. C. Desrosiers, and B. Fleckenstein.
1992.
Stable growth transformation of human T lymphocytes by herpesvirus saimiri.
Proc. Natl. Acad. Sci. USA
89:3116-3119[Abstract/Free Full Text].
|
| 5.
|
Bublot, M.,
E. Manet,
A. S. Lequarre,
J. C. Albrecht,
J. Nicholas,
B. Fleckenstein,
P. P. Pastoret, and E. Thiry.
1992.
Genetic relationships between bovine herpesvirus 4 and the gamma-herpesviruses Epstein-Barr and herpesvirus saimiri.
Virology
190:654-665[Medline].
|
| 6.
|
Caron, C.,
R. Rousset,
C. Beraud,
V. Moncollin,
J.-M. Egly, and P. Jalinot.
1993.
Functional and biochemical interaction of the HTLV-1 tax1 transactivator with TBP.
EMBO J.
12:4269-4278[Medline].
|
| 7.
|
Chang, J.,
D.-H. Kim,
S. W. Lee,
K. Y. Choi, and Y. C. Sung.
1995.
Transactivation ability of p53 transcriptional activation domain is directly related to the binding affinity to TATA-binding protein.
J. Biol. Chem.
42:25014-25019.
|
| 8.
|
Chen, X.,
G. Farmer,
H. Zhu,
R. Prywes, and C. Prives.
1993.
Cooperative binding of p53 with TFIID (TBP): a possible mechanism for transcriptional activation.
Genes Dev.
7:1837-1849[Abstract/Free Full Text].
|
| 9.
|
Choy, B., and M. R. Green.
1993.
Eukaryotic activators function during multiple steps of preinitiation complex assembly.
Nature (London)
366:531-536[Medline].
|
| 10.
|
Cress, W. D., and S. J. Triezenberg.
1991.
Critical structure elements of the VP16 transcriptional activation domain.
Science
251:87-90[Abstract/Free Full Text].
|
| 11.
|
Fleckenstein, B., and R. C. Desrosiers.
1982.
Herpesvirus saimiri and herpesvirus ateles, p. 253-332.
In
B. Roizman (ed.), The herpesviruses, vol. 1. Plenum Press, New York, N.Y
|
| 12.
|
Gill, G. E.,
E. Pascal,
Z. H. Tseng, and R. Tjian.
1994.
A glutamine-rich hydrophobic patch in transcription factor Sp1 contacts the dTAFII110 component of the Drosophila TFIID complex and mediates transcriptional activation.
Proc. Natl. Acad. Sci. USA
91:192-196[Abstract/Free Full Text].
|
| 13.
|
Gompels, U. A.,
M. A. Craxton, and R. W. Honess.
1988.
Conservation of gene organization in the lymphotrophic herpesvirus saimiri.
J. Virol.
62:757-767[Abstract/Free Full Text].
|
| 14.
|
Gompels, U. A.,
M. A. Craxton, and R. W. Honess.
1988.
Conservation of glycoprotein H (gH) in herpesvirus: nucleotide sequence of the gH gene from herpesvirus saimiri.
J. Gen. Virol.
69:2819-2829[Abstract/Free Full Text].
|
| 15.
|
Gorman, C. M.,
L. F. Moffat, and B. H. Howard.
1982.
Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.
Mol. Cell. Biol.
2:1044-1051[Abstract/Free Full Text].
|
| 16.
|
Gruffat, H., and A. Sergeant.
1994.
Characterization of the DNA-binding site repertoire for the Epstein-Barr virus transcription factor R.
Nucleic Acids Res.
22:1172-1178[Abstract/Free Full Text].
|
| 17.
|
Gruffat, H.,
E. Manet,
A. Rigolet, and A. Sergeant.
1990.
The enhancer factor R of Epstein-Barr virus (EBV) is a sequence specific DNA binding protein.
Nucleic Acids Res.
18:6835-6843[Abstract/Free Full Text].
|
| 18.
|
Gruffat, H.,
N. Duran,
M. Buisson,
F. Wild,
R. Buckland, and A. Sergeant.
1992.
Characterization of an R-binding site mediating the R-induced activation of the Epstein-Barr virus BMLF1 promoter.
J. Virol.
66:46-52[Abstract/Free Full Text].
|
| 19.
|
Hagemeier, C.,
A. Cook, and T. Kouzarides.
1993.
The retinoblastoma protein binds E2F residues required for activation in vivo and TBP binding in vitro.
Nucleic Acids Res.
21:4998-5004[Abstract/Free Full Text].
|
| 20.
|
Hardwicke, J. M.,
L. Tse,
N. Applegren,
J. Nicholas, and M. A. Veliuona.
1992.
The Epstein-Barr virus R transactivator (Rta) contains a complex, potent activator domain with properties different from those of VP16.
J. Virol.
66:5500-5508[Abstract/Free Full Text].
|
| 21.
|
Hardwicke, J. M.,
P. M. Liberman, and S. D. Hayward.
1988.
A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen.
J. Virol.
62:2274-2284[Abstract/Free Full Text].
|
| 22.
|
Hateboer, G.,
H. T. M. Timmers,
A. K. Rustgi,
M. Billaud,
L. J. van't Veer, and R. Bernards.
1993.
TATA-binding protein and the retinoblastoma gene product bind to overlapping epitopes on c-Myc and adenovirus E1A protein.
Proc. Natl. Acad. Sci. USA
90:8489-8493[Abstract/Free Full Text].
|
| 23.
|
Ingles, C. J.,
M. Shales,
W. D. Cress,
S. J. Triezenberg, and J. Greenblatt.
1991.
Reduced binding of TFIID to transcriptionally compromised mutants of VP16.
Nature (London)
351:588-590[Medline].
|
| 24.
|
Johnston, S. A.,
M. J. Zavortink,
C. Debouck, and J. E. Hopper.
1986.
Functional domains of the yeast regulatory protein GAL4.
Proc. Natl. Acad. Sci. USA
83:6553-6557[Abstract/Free Full Text].
|
| 25.
|
Kashanchi, F.,
G. Piras,
M. F. Radonovich,
J. F. Duvall,
A. Fattaey,
C.-M. Chiang,
R. G. Roeder, and J. N. Brady.
1994.
Direct interaction of human TFIID with the HIV-1 transactivator Tat.
Nature (London)
367:295-299[Medline].
|
| 26.
|
Lee, W. S.,
C. C. Kao,
G. O. Bryant,
X. Liu, and A. J. Berk.
1991.
Adenovirus EIA transactivation domain binds the basic repeat in the TATA box transcription factor.
Cell
67:365-376[Medline].
|
| 27.
|
Leuther, K. K.,
J. M. Salmeron, and S. A. Johnston.
1993.
Genetic evidence that an activation domain of GAL4 does not require acidity and may form a sheet.
Cell
72:575-585[Medline].
|
| 28.
|
Lieberman, P. M., and A. J. Berk.
1991.
The Zta transactivator protein stabilises TFIID association with promoter DNA by direct protein-protein interactions.
Genes Dev.
5:2441-2554[Abstract/Free Full Text].
|
| 29.
|
Lillie, J. W., and M. R. Green.
1989.
Transcription activation by the adenovirus E1A protein.
Nature (London)
338:39-44[Medline].
|
| 30.
|
Lin, J.,
J. Chen,
B. Elenbaas, and A. J. Levine.
1994.
Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.
Genes Dev.
8:1235-1246[Abstract/Free Full Text].
|
| 31.
|
Lin, Y., and M. R. Green.
1991.
Mechanism of action of an acidic transcriptional activator in vitro.
Cell
64:971-981[Medline].
|
| 32.
|
Liu, X.,
C. W. Miller,
P. H. Koeffler, and A. J. Berk.
1993.
The p53 activation domain binds the TATA-box binding polypeptide in holo-TFIID, and a neighboring p53 domain inhibits transcription.
Mol. Cell. Biol.
13:3291-3300[Abstract/Free Full Text].
|
| 33.
|
Manet, E.,
A. Rigolet,
H. Gruffat,
J. F. Giot, and A. Sergeant.
1991.
Domains of the Epstein-Barr virus transcription factor R required for dimerisation, DNA binding and activation.
Nucleic Acids Res.
19:2661-2667[Abstract/Free Full Text].
|
| 34.
|
Manet, E.,
C. Allera,
H. Gruffat,
I. Mikaelian,
A. Rigolet, and A. Sergeant.
1993.
The acidic activation domain of the EBV transcription factor interacts in vitro with both TBP and TFIIB and is cell-specifically potentiated by a proline-rich region.
Gene Expr.
3:49-59[Medline].
|
| 35.
|
Martin, D. W.,
R. M. Munoz,
M. A. Subler, and S. Deb.
1993.
p53 binds to the TATA-binding protein-TATA complexes.
J. Biol. Chem.
268:13062-13067[Abstract/Free Full Text].
|
| 36.
|
Mazzarelli, J. M.,
G. Mengus,
I. Davidson, and R. P. Ricciardi.
1997.
The transactivation domain of adenovirus E1A interacts with the C terminus of human TAFII135.
J. Virol.
71:7978-7983[Abstract].
|
| 37.
|
Metz, R.,
A. J. Bannister,
J. A. Sutherland,
C. Hagemeier,
E. C. O'Rourke,
A. Cook,
R. Bravo, and T. Kouzarides.
1994.
c-Fos-induced activation of a TATA-box-containing promoter involves direct contact with TATA-binding protein.
Mol. Cell. Biol.
14:6021-6029[Abstract/Free Full Text].
|
| 38.
|
Mitchell, P. J., and R. Tjian.
1989.
Transcriptional regulation in mammalian cells by sequence specific DNA binding proteins.
Science
245:371-378[Abstract/Free Full Text].
|
| 39.
|
Neipel, F.,
J. C. Albrecht, and B. Fleckenstein.
1997.
Cell-homologous genes in Kaposi's sarcoma associated rhadinovirus human herpesvirus 8: determinants of its pathogenicity?
J. Virol.
71:4187-4192[Medline].
|
| 40.
|
Nicholas, J.,
K. R. Cameron,
H. Coleman,
C. Newman, and R. W. Honess.
1992.
Analysis of nucleotide sequence of the rightmost 43 kbp of herpesvirus saimiri (HVS) L-DNA: general conservation of genetic organization between HVS and Epstein-Barr virus.
Virology
188:296-310[Medline].
|
| 41.
|
Nicholas, J.,
L. S. Coles,
C. Newman, and R. W. Honess.
1991.
Regulation of the herpesvirus saimiri (HVS) delayed-early 110-kilodalton promoter by HVS immediate-early gene products and a homolog of the Epstein-Barr virus R trans activator.
J. Virol.
65:2457-2466[Abstract/Free Full Text].
|
| 42.
|
Nicholas, J.,
U. A. Gompels,
M. A. Craxton, and R. W. Honess.
1988.
Conservation of sequence and function between the product of the 52-kilodalton immediate-early gene of the herpesvirus saimiri and the BMLF1-encoded transcriptional effector (EB2) of the Epstein-Barr virus.
J. Virol.
62:3250-3257[Abstract/Free Full Text].
|
| 43.
|
Ptashne, M.
1988.
How eukaryotic transcriptional activators work.
Nature (London)
335:683-689[Medline].
|
| 44.
|
Ransone, L. J.,
L. D. Kerr,
M. J. Schmitt,
P. Wamsley, and I. M. Verma.
1993.
The bZIP domains of Fos and Jun mediate a physical association with the TATA box-binding protein.
Gene Expr.
3:37-48[Medline].
|
| 45.
|
Roeder, R. G.
1996.
The role of general initiation factors in transcription by RNA polymerase II.
Trends Biochem. Sci.
21:327-335[Medline].
|
| 46.
|
Russo, J. J.,
R. A. Bohenzhy,
M. C. Chein,
J. Chen,
M. Yan,
D. Maddalena,
J. P. Parry,
D. Peruzzi,
I. S. Edelman,
Y. Chang, and P. S. Moore.
1996.
Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8).
Proc. Natl. Acad. Sci. USA
93:14862-14867[Abstract/Free Full Text].
|
| 47.
|
Seto, E.,
A. Usheva,
P. Zambetti,
J. Momand,
N. Horikoshi,
R. Weinmann, and T. Shenk.
1992.
Wild-type p53 binds to the TATA-binding protein and represses transcription.
Proc. Natl. Acad. Sci. USA
89:12028-12032[Abstract/Free Full Text].
|
| 48.
|
Stringer, K. F.,
C. J. Ingles, and J. Greenbalt.
1990.
Direct and selective binding of an acidic transcriptional activation domain to the TATA-box factor TFIID.
Nature (London)
345:783-786[Medline].
|
| 49.
|
Truant, R.,
H. Xiao,
C. J. Ingles, and J. Greenblat.
1993.
Direct interaction between the transcriptional activation domain of human p53 and the TATA-box binding protein.
J. Biol. Chem.
268:2284-2287[Abstract/Free Full Text].
|
| 50.
|
Verrijer, C. P., and R. Tjian.
1996.
TAFs mediate transcriptional activation and promoter selectivity.
Trends Biochem. Sci.
21:338-342[Medline].
|
| 51.
|
Virgin, H. W.,
P. Latreille,
P. Wamsley,
K. Hallsworth,
K. E. Weck,
A. J. Dal Canto, and S. H. Speck.
1997.
Complete sequence and genomic analysis of murine gammaherpesvirus 68.
J. Virol.
71:5894-5904[Abstract].
|
| 52.
|
Whitehouse, A.,
I. M. Carr,
J. C. Griffiths, and D. M. Meredith.
1997.
The herpesvirus saimiri ORF 50 gene, encoding a major transcriptional activator homologous to the Epstein-Barr virus R protein, is transcribed from two distinct promoters of different temporal phases.
J. Virol.
71:2550-2554[Abstract].
|
| 53.
|
Whitehouse, A.,
A. J. Stevenson,
M. Cooper, and D. M. Meredith.
1997.
Identification of a cis-acting element within the herpesvirus saimiri ORF6 promoter that is responsive to the HVS.R transactivator.
J. Gen. Virol.
78:1411-1415[Abstract].
|
| 54.
|
Whitehouse, A.,
M. Cooper, and D. M. Meredith.
1998.
The immediate-early gene product encoded by open reading frame 57 of herpesvirus saimiri modulates gene expression at a posttranscriptional level.
J. Virol.
72:857-861[Abstract/Free Full Text].
|
| 55.
|
Whitehouse, A.,
M. Cooper,
K. T. Hall, and D. M. Meredith.
1998.
The open reading frame (ORF) 50a gene product regulates ORF 57 gene expression in herpesvirus saimiri.
J. Virol.
72:1967-1973[Abstract/Free Full Text].
|
| 56.
|
Xu, X.,
C. Prorock,
H. Ishikawa,
E. Maldonado,
Y. Ito, and C. Gelinas.
1993.
Functional interaction of the v-Rel and c-Rel oncoproteins with the TATA-binding protein and association with transcription factor IIB.
Mol. Cell. Biol.
13:6733-6741[Abstract/Free Full Text].
|
| 57.
|
Yankulov, K.,
J. Blau,
T. Purton,
S. Roberts, and D. L. Bentley.
1994.
Transcriptional elongation by RNA polymerase II is stimulated by transactivators.
Cell
77:749-759[Medline].
|
Journal of Virology, December 1999, p. 9756-9763, Vol. 73, No. 12
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Gould, F., Harrison, S. M., Hewitt, E. W., Whitehouse, A.
(2009). Kaposi's Sarcoma-Associated Herpesvirus RTA Promotes Degradation of the Hey1 Repressor Protein through the Ubiquitin Proteasome Pathway. J. Virol.
83: 6727-6738
[Abstract]
[Full Text]
-
Wakenshaw, L., Walters, M. S., Whitehouse, A.
(2005). The Herpesvirus Saimiri Replication and Transcription Activator Acts Synergistically with CCAAT Enhancer Binding Protein Alpha To Activate the DNA Polymerase Promoter. J. Virol.
79: 13548-13560
[Abstract]
[Full Text]
-
Walters, M. S., Hall, K. T., Whitehouse, A.
(2005). The herpesvirus saimiri Rta gene autostimulates via binding to a non-consensus response element. J. Gen. Virol.
86: 581-587
[Abstract]
[Full Text]
-
Amon, W., Binne, U. K., Bryant, H., Jenkins, P. J., Karstegl, C. E., Farrell, P. J.
(2004). Lytic Cycle Gene Regulation of Epstein-Barr Virus. J. Virol.
78: 13460-13469
[Abstract]
[Full Text]
-
Jung Song, M., Hwang, S., Wong, W., Round, J., Martinez-Guzman, D., Turpaz, Y., Liang, J., Wong, B., Johnson, R. C., Carey, M., Sun, R.
(2004). The DNA Architectural Protein HMGB1 Facilitates RTA-Mediated Viral Gene Expression in Gamma-2 Herpesviruses. J. Virol.
78: 12940-12950
[Abstract]
[Full Text]
-
Walters, M. S., Hall, K. T., Whitehouse, A.
(2004). The Herpesvirus Saimiri Open Reading Frame (ORF) 50 (Rta) Protein Contains an AT Hook Required for Binding to the ORF 50 Response Element in Delayed-Early Promoters. J. Virol.
78: 4936-4942
[Abstract]
[Full Text]
-
Schafer, A., Lengenfelder, D., Grillhosl, C., Wieser, C., Fleckenstein, B., Ensser, A.
(2003). The Latency-Associated Nuclear Antigen Homolog of Herpesvirus Saimiri Inhibits Lytic Virus Replication. J. Virol.
77: 5911-5925
[Abstract]
[Full Text]
-
Ueda, K., Ishikawa, K., Nishimura, K., Sakakibara, S., Do, E., Yamanishi, K.
(2002). Kaposi's Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) Replication and Transcription Factor Activates the K9 (vIRF) Gene through Two Distinct cis Elements by a Non-DNA-Binding Mechanism. J. Virol.
76: 12044-12054
[Abstract]
[Full Text]
-
Goodwin, D. J., Walters, M. S., Smith, P. G., Thurau, M., Fickenscher, H., Whitehouse, A.
(2001). Herpesvirus Saimiri Open Reading Frame 50 (Rta) Protein Reactivates the Lytic Replication Cycle in a Persistently Infected A549 Cell Line. J. Virol.
75: 4008-4013
[Abstract]
[Full Text]
-
Goodwin, D. J., Hall, K. T., Giles, M. S., Calderwood, M. A., Markham, A. F., Whitehouse, A.
(2000). The carboxy terminus of the herpesvirus saimiri ORF 57 gene contains domains that are required for transactivation and transrepression. J. Gen. Virol.
81: 2253-2265
[Abstract]
[Full Text]